SGLT-2 inhibitors can be used in pasireotide-treated patients with CD or acromegaly with worsening hyperglycemia or newly diagnosed diabetes, with metformin as monotherapy or in combination with DPP-4 inhibitors or GLP-1 RAs (69, 71). Here, SLC5A2 is linked to Hyperglycemia.